Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, an RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-N531, an exon skipping oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.

Period	fcf
2015-12-31	-$14.38M
2016-12-31	-$37.44M
2017-12-31	-$102.56M
2018-12-31	-$32.78M
2019-12-31	-$192.15M
2020-12-31	-$117.32M
2021-12-31	-$89.55M
2022-12-31	-$129.14M
2023-12-31	-$20.55M
2024-12-31	-$151.96M

	A	B	C	D
1	Symbol	Price	Change	Volume
2	WVE	$7.28	+0.00%	4.07M
3
4
5

Wave Life Sciences Ltd. (WVE) Free Cash Flow

Free Cash Flow Data

Get Wave Life Sciences Ltd. Data in Excel

More WVE Financial Data